Classic Hallucinogens and Mystical Experiences: Phenomenology and Neural Correlates Read More > March 26, 2017
Conducting Qualitative Research With Psychedelic Psychopharmacologists: Challenges of Co-Production in an Era of Interdisciplinarity Read More > March 3, 2017
Metabolism of psilocybin and psilocin: clinical and forensic toxicological relevance Read More > January 31, 2017
The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Bouso et al., 2016 Read More > January 25, 2017
The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Barrett & Griffiths (2016) Read More > January 25, 2017
The factor structure of the Mystical Experience Questionnaire (MEQ): Reply to Barrett & Griffiths (2016) Read More > January 25, 2017
The fibrinolytic system: A new target for treatment of depression with psychedelics Read More > January 23, 2017
Clinical potential of psilocybin as a treatment for mental health conditions Read More > January 1, 2017
Psilocybin: promising results in double-blind trials require confirmation by real-world evidence Read More > December 6, 2016
